Cargando…
Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
BACKGROUND AND AIMS: Early prediction of the effect of vedolizumab (VDZ) in inflammatory bowel disease (IBD) is of paramount importance to guide clinical decisions. This study assessed whether early fecal calprotectin (FC) can predict endoscopic response and histologic remission after VDZ initiation...
Autores principales: | Pauwels, Renske W. M., van der Woude, Christien J., Erler, Nicole S., de Vries, Annemarie C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768861/ https://www.ncbi.nlm.nih.gov/pubmed/33488771 http://dx.doi.org/10.1177/1756284820979765 |
Ejemplares similares
-
Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice
por: Pauwels, Renske Wilhelmina Maria, et al.
Publicado: (2020) -
Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease
por: Pauwels, Renske W M, et al.
Publicado: (2021) -
Association of Fecal Calprotectin With Endoscopic and Histologic Activity in Pediatric Inflammatory Bowel Disease
por: Crawford, Erin, et al.
Publicado: (2021) -
Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
por: Zou, Fangwen, et al.
Publicado: (2021) -
Correction: Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
Publicado: (2021)